Womack Financial LLC Takes Position in Medpace Holdings, Inc. $MEDP

Womack Financial LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,175 shares of the company’s stock, valued at approximately $1,152,000. Medpace accounts for about 0.8% of Womack Financial LLC’s holdings, making the stock its 24th largest holding.

A number of other large investors have also recently made changes to their positions in the company. BOKF NA lifted its stake in Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after acquiring an additional 20 shares during the last quarter. Valeo Financial Advisors LLC increased its position in shares of Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after purchasing an additional 21 shares during the last quarter. UMB Bank n.a. increased its position in shares of Medpace by 5.6% in the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after purchasing an additional 24 shares during the last quarter. Schulhoff & Co. Inc. raised its holdings in shares of Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after purchasing an additional 25 shares in the last quarter. Finally, Balefire LLC raised its holdings in shares of Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after purchasing an additional 26 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Medpace

In other news, Director Cornelius P. Mccarthy III sold 1,140 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the sale, the director owned 12,275 shares in the company, valued at $7,430,916.75. This trade represents a 8.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total value of $4,414,590.45. Following the completion of the transaction, the director owned 3,798 shares of the company’s stock, valued at $2,302,157.70. The trade was a 65.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 125,661 shares of company stock worth $73,854,945 in the last three months. 20.50% of the stock is currently owned by company insiders.

Medpace Price Performance

Medpace stock opened at $620.03 on Tuesday. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The stock has a market capitalization of $17.31 billion, a P/E ratio of 36.34, a P/E/G ratio of 2.77 and a beta of 1.15. The firm’s 50-day moving average is $553.21 and its two-hundred day moving average is $492.40.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Robert W. Baird boosted their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 price objective on Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada increased their price objective on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Finally, Mizuho upped their price target on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, Medpace presently has an average rating of “Hold” and an average price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.